Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms

Seung Koo Yang, Seong Ho Cho, Dae Woo Kim

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease treated with medication or surgery. For recalcitrant type 2 CRSwNP, biological agents have been effectively used to improve nasal polyp score, nasal congestion score, daily symptoms related to CRSwNP, and time to systemic corticosteroid use or revision surgery. Although general guidelines for using biologics to treat CRSwNP were proposed by the European Position Paper on Rhinosinusitis and Nasal Polyps in 2020 and various studies have tested their efficacy, there is much more to learn about biologics-specific indication and choice of biologics based on the endotypes, for instance. Understanding the vascular distribution of monoclonal antibodies and the differences in the vascularity of the non-polyp mucosa and nasal polyp tissue will not only aid understanding of each biologic's clinical effect but also provide insights to establishing a more personalized approach to treating recalcitrant CRSwNP with biologics.

Original languageEnglish
Pages (from-to)465-478
Number of pages14
JournalAllergy, Asthma and Immunology Research
Volume14
Issue number5
DOIs
StatePublished - Sep 2022
Externally publishedYes

Keywords

  • Chronic rhinosinusitis
  • benralizumab
  • dupilumab
  • mepolizumab
  • nasal congestion score
  • nasal polyp
  • nasal polyp score
  • olfaction
  • omalizumab
  • reslizumab

Fingerprint

Dive into the research topics of 'Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms'. Together they form a unique fingerprint.

Cite this